
Phase 3 41 items
Trials, agents, guidance
- Trial MOVE-Lp(a) (muvalaplin outcomes)
- Trial ACCLAIM-Lp(a)
- Trial OCEAN(a)-Outcomes
- Trial Lp(a)FRONTIERS APHERESIS
- Trial Lp(a)HORIZON
Studies
- Lp(a)HORIZON: pelacarsen lowers Lp(a) by 78 percent but does not reduce cardiovascular events, hazard ratio 1.02 (Cho et al., NEJM 2026)
- Lp(a)FRONTIERS APHERESIS: pelacarsen replaces lipoprotein apheresis in 25 of 26 patients (Parhofer et al., EHJ 2026)
- Design and rationale of Lp(a)HORIZON, the first Lp(a) outcomes trial: pelacarsen in 8,323 patients (Cho, Nicholls, Nordestgaard et al., Am Heart J 2025)
- Alirocumab cuts cardiovascular events regardless of sex, with a larger benefit at higher baseline Lp(a) in women, ODYSSEY OUTCOMES (J Clin Lipidol 2024)
- Lp(a) reduction from PCSK9 inhibition does not independently lower cardiovascular events, a pooled analysis of 10 phase 3 alirocumab trials in 4983 patients (Atherosclerosis 2019)
- Mass, molar and mass-spectrometry Lp(a) assays predict cardiovascular risk and alirocumab benefit equally in 11,970 ODYSSEY OUTCOMES patients (Circulation 2024)
- Pelacarsen cut Lp(a) by 80% in phase 2, letting 98% of patients reach target levels, as the 7,680-patient Lp(a)HORIZON outcomes trial enrolls, a JACC Focus Seminar (J Am Coll Cardiol 2021)
- PCSK9 inhibition lowers LDL cholesterol and Lp(a) discordantly in 20% of patients, a pooled analysis of 4 phase 3 evolocumab trials in 895 patients (J Am Heart Assoc 2019)
- Alirocumab sustainably lowers Lp(a) by up to 29% over 1.5 years, a pooled analysis of 10 phase 3 ODYSSEY trials in 4915 patients (Am J Cardiol 2017)
- Mipomersen cuts Lp(a) by 26% across diverse hypercholesterolaemia populations, a pooled analysis of 4 phase 3 trials and 382 patients (Arterioscler Thromb Vasc Biol 2015)
- About 20% of people carry elevated Lp(a), and phase 3 outcome trials of pelacarsen and olpasiran are now testing whether lowering it reduces cardiovascular events (Annu Rev Pharmacol Toxicol 2024)
- Every RNA-based Lp(a) drug tested lowers it by more than 90%, a systematic assessment of 22 trials of pelacarsen, olpasiran, SLN360 and LY3819469 (J Cardiovasc Pharmacol 2023)
- Elevated Lp(a) (>=200 nmol/L) raises cardiovascular event risk by 33% in a cohort mirroring the OCEAN(a)-Outcomes trial population, 3,142 patients (Eur Heart J Open 2023)
- Trial design challenges for Lp(a)-lowering therapies take center stage as pelacarsen and olpasiran enter phase 3 outcomes trials, a JACC Focus Seminar (J Am Coll Cardiol 2023)
- Pelacarsen lowers Lp(a) by up to 106% in healthy Japanese subjects, supporting the 80 mg monthly dose used in the Lp(a)HORIZON trial (J Clin Lipidol 2023)
- Alirocumab LDL-C and Lp(a)-lowering effects are discordant in 21.5% of patients, suggesting separate clearance pathways, a pooled analysis of 1,709 patients across 10 ODYSSEY phase 3 trials (Eur J Prev Cardiol 2021)
- Lepodisiran advances to phase 3 ACCLAIM-Lp(a) outcomes trial, updated review (Cardiol Rev 2026)
- About a quarter of the world has Lp(a) above 50 mg/dL, and gene-silencing drugs dosed a few times a year could finally lower it robustly, a review (Curr Vasc Pharmacol 2024)
- Olpasiran and pelacarsen could be cost-effective at AU$1867 and AU$984 per year for secondary prevention of coronary heart disease, an early Australian health technology assessment (J Clin Lipidol 2024)
- Pelacarsen, olpasiran and SLN360 lower Lp(a) by up to 90%, with pelacarsen phase 3 outcome trial due in 2024, a review (Curr Atheroscler Rep 2022)
- Over 20% of the population has Lp(a) above 50 mg/dL, and antisense oligonucleotides can cut it by up to 90% as the Lp(a)HORIZON outcomes trial nears results, a review (Curr Atheroscler Rep 2021)
- Genetics explains 80-90% of Lp(a) variation, up to 1000-fold between people, and antisense drugs can cut it 80% as the HORIZON trial nears, a review (Curr Atheroscler Rep 2021)
- Antisense drug AKCEA-APO(a)-LRx cuts Lp(a) by up to 80% as a phase 3 outcomes trial is planned, a review of antisense oligonucleotides for Lp(a) (Curr Atheroscler Rep 2019)
- Guidelines recommend once-in-a-lifetime Lp(a) measurement in nmol/L for all adults (Clin Chem 2026)
- Pelacarsen and Lp(a)HORIZON: interpreting the disconnect between lipoprotein(a) lowering and cardiovascular outcomes (Am J Med 2026)
- As Lp(a)-lowering drugs enter outcome trials, should everyone be screened? A review by a leading cardiologist weighs the case (Curr Cardiol Rep 2021)
- Antisense apo(a) inhibitors could pair with statins for patients with both high Lp(a) and high LDL, as phase 3 data approaches, a review (Eur J Intern Med 2020)
Video and podcasts


AHA 2026: Lp(a)HORIZON, does lowering Lp(a) reduce cardiovascular risk? (Steven Nissen with Harriette Van Spall)
Timeline
- OCEAN(a)-PreEvent primary completion (olpasiran, primary prevention)
- MOVE-Lp(a) primary completion (muvalaplin)
- ACCLAIM-Lp(a) primary completion (lepodisiran)
- OCEAN(a)-Outcomes result (olpasiran)
- Lp(a)HORIZON result (pelacarsen): neutral
- Lp(a)FRONTIERS APHERESIS published: pelacarsen replaces apheresis
- Lp(a)HORIZON completes enrolment (8,323 patients)